Sionna Therapeutics

Sionna makes medicines for people with cystic fibrosis. These treatments help a specific protein work normally. The company wants to improve how patients feel daily.

Targeting the Root Cause

• NBD1 Stabilizers: Oral drugs designed to fix the shape of a vital protein; currently in Phase 1 and Phase 2 testing.
• Complementary Modulators: Correctors that help transport proteins to the cell surface; intended for use in dual combinations.
• Potentiators: Medicines that help open salt channels in cells; used to boost the effect of other treatments in the pipeline.

Strategic Moves and Partnerships

• Licensed several drug candidates from AbbVie Global Enterprises Ltd. to expand its pipeline of potential combination therapies.
• Acquired rights to SION-2851 from AbbVie in July 2024 to strengthen its portfolio of protein-correcting medicines.
• Collaborated with Sanofi to develop and commercialize specific compounds used in its lead product candidates.
• Started the PreciSION CF Phase 2a trial in October 2025 to test treatments alongside existing standards of care.

What Sets Sionna Apart

Sionna uses a specialized lab model with human lung cells to predict if a drug will work. This approach helps the company choose the most effective medicines before they are tested in large patient trials.

By the Numbers

• Net income was -$20.4 million in Q4 2025, which deepened 29% from Q4 2024.
• Operating income worsened to -$23.6 million in Q4 2025, down 30.2% year-over-year.
• Free cash flow hit -$16.8 million in Q4 2025, a decrease of 42.5% from the previous year.
• Market capitalization reached $1.6 billion in Q4 2025, up 49% from $1.1 billion in Q4 2024.

The Bottom Line

Sionna is transitioning from a research firm to a clinical-stage company testing potential new therapies. Its focus on fixing the core protein defect in cystic fibrosis defines its current strategy and development pipeline.